EyePoint Pharmaceuticals, Inc. Nonoperating Income (Expense) in USD from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
EyePoint Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to Q3 2025.
  • EyePoint Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $2.29M, a 32.3% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $12.8M, a 5.36% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $15.1M, a 246% increase from 2023.
  • EyePoint Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $4.36M.
  • EyePoint Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$2.62M, a 16.7% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

EyePoint Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $12.8M $2.29M -$1.09M -32.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $13.9M $2.89M -$826K -22.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $14.7M $3.64M -$395K -9.78% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $15.1M $3.93M +$1.59M +68.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 $13.5M $3.39M +$1.6M +89.6% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $11.9M $3.72M +$3.88M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $8M $4.04M +$3.65M +935% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $4.36M $2.34M +$2.05M +715% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 $2.3M $1.79M +$1.81M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $496K -$159K +$31K +16.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $465K $390K +$3.08M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$2.62M $287K +$1.67M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 -$4.29M -$22K +$1.36M +98.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$5.65M -$190K -$1.16M -120% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$4.49M -$2.69M -$1.35M -100% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$3.14M -$1.38M +$1.35M +49.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-10
Q3 2021 -$4.49M -$1.38M +$462K +25.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$4.95M $969K +$2.77M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$7.72M -$1.35M +$385K +22.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$8.1M -$2.73M -$1.31M -91.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$6.8M -$1.84M -$257K -16.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$6.54M -$1.8M -$465K -34.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$6.08M -$1.73M +$2.86M +62.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$8.93M -$1.43M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$1.59M +$18M +91.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$1.33M +$23.3M +94.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$4.59M -$2.29M -99.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q3 2018 -$19.6M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$24.6M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$2.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q1 2015 $10K +$9K Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-08
Q2 2014 $5K $2K $0 0% Apr 1, 2014 Jun 30, 2014 10-K 2015-09-10
Q1 2014 $5K $1K* -$2K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 $7K $1K* -$2K Oct 1, 2013 Dec 31, 2013 10-Q 2014-02-12
Q3 2013 $9K $1K* -$5K Jul 1, 2013 Sep 30, 2013 10-Q 2013-11-13
Q2 2013 $14K $2K -$6K -75% Apr 1, 2013 Jun 30, 2013 10-K 2015-09-10
Q1 2013 $20K $3K -$8K -72.7% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q4 2012 $28K $3K -$136K -97.8% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-12
Q3 2012 $164K $6K -$43K -87.8% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 $207K $8K -$11K -57.9% Apr 1, 2012 Jun 30, 2012 10-K 2014-09-11
Q1 2012 $218K $11K -$330K -96.8% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-14
Q4 2011 $548K $139K -$322K -69.8% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-08
Q3 2011 $870K $49K -$287K -85.4% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 $1.16M $19K Apr 1, 2011 Jun 30, 2011 10-K 2013-09-27
Q1 2011 $341K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
Q4 2010 $461K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-09
Q3 2010 $336K Jul 1, 2010 Sep 30, 2010 10-Q/A 2011-11-09

EyePoint Pharmaceuticals, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15.1M +$10.7M +246% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 $4.36M +$6.97M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 -$2.62M +$524K +16.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-08
2021 -$3.14M +$4.96M +61.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-10
2020 -$8.1M +$828K +9.27% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 -$8.93M +$18M +66.8% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-12
2018 -$26.9M -$27M -29657% Jul 1, 2017 Jun 30, 2018 10-K 2020-03-16
2017 $91K Jul 1, 2016 Jun 30, 2017 10-K 2020-03-16
2015 $22K +$17K +340% Jul 1, 2014 Jun 30, 2015 10-K 2015-09-10
2014 $5K -$9K -64.3% Jul 1, 2013 Jun 30, 2014 10-K 2015-09-10
2013 $14K -$193K -93.2% Jul 1, 2012 Jun 30, 2013 10-K 2015-09-10
2012 $207K -$950K -82.1% Jul 1, 2011 Jun 30, 2012 10-K 2014-09-11
2011 $1.16M +$1.47M Jul 1, 2010 Jun 30, 2011 10-K 2013-09-27
2010 -$315K Jul 1, 2009 Jun 30, 2010 10-K 2012-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.